PUBLIC COMPANY
saveParabilis Medicines
updated 2mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Scribe’s early-stage IPO standout defies biotech’s derisking trendScribe Therapeutics’ one-time epigenetic treatment is designed to slash the adherence burden of chronic cholesterol-lowering therapies while sidestepping the irreversibility of gene editing.biospace · 11h ago
- Regeneron ends eye disease study due to antibody's safety profileThe discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen fo…biospace · 2d ago
- Regeneron ends eye disease study due to antibody's safety profileThe discontinuation of the uveitis study adds to Regeneron’s series of clinical setbacks, including the Phase 3 failures of the Dupixent follow-up itepekimab and an investigational combo regimen fo…biospace · 2d ago
- With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug developmentAI is quickly becoming a central force in drug development, from powering pharma engines to permanently rewiring the capital markets.biospace · 8d ago
- 2026 Q2 Job Market Report: Job postings keep rising as fewer companies cut employeesJob postings increase and competition dips, according to BioSpace data.biospace · 13d ago
- BlossomHill, Latigo outshine IPO expectations with oversubscribed debutsTwo growing biotechs blasted through their IPO expectations Friday, with Blossom Hill Therapeutics and Latigo Biotherapeutics each raising at least 30% more than expected in their stock market debuts.fiercebiotech · 13d ago
- With $263M, LifeMine unearths a new drug for organ transplantsLed by serial biotech entrepreneur Greg Verdine, the startup mined fungi genomes to find a safer alternative to the drugs widely used to prevent the body from rejecting transplanted organs.biopharma_dive · 14d ago
- Braveheart charges past expectations with $382.5M IPO to fund cardio drug from HengruiBraveheart Bio has overcome its own IPO expectations, rallying $382.5 million in an upsized listing to fund its cardiovascular ambitions.fiercebiotech · 14d ago
- ‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series EA little over a year ago, LifeMine Therapeutics laid off staff and put its fungus-based platform on ice to focus its dwindling resources on its lead asset. Now, the Massachusetts biotech is shaking…fiercebiotech · 15d ago
- Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launchApnimed has raised $192 million for its upsized IPO, with the proceeds earmarked to fund the launch of its sleep apnea pill.fiercebiotech · 20d ago
comments(0)
5-min edit window · permanent after that